Literature DB >> 8763991

Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals.

Q Y Yao1, R J Tierney, D Croom-Carter, D Dukers, G M Cooper, C J Ellis, M Rowe, A B Rickinson.   

Abstract

The Epstein-Barr virus (EBV) carrier state is characterized by latent infection of the general B-cell pool and by chronic virus replication at oropharyngeal sites. In Caucasian populations, most healthy carriers seem to harbor one dominant transforming virus strain, usually of type I rather than type 2, which persists over time and is detectable both in the blood and in the throat. This finding implies that once the virus carrier state is established, both viral reservoirs are largely if not completely protected from infection with additional strains. However, it is not known which facets of the immune response offer that protection. Here we address this question by a detailed study of EBV carriage in patients T-cell immunocompromised as a result of chronic human immunodeficiency virus (HIV) infection. Resident EBV strains were rescued from blood and from throat washings by using an in vitro transformation assay which aims to minimize bias toward faster-growing transformants; in this way, a mean of 16 independent isolations were made from each of 35 HIV-positive (predominantly male homosexual) patients. These virus isolates were characterized first at the DNA level by PCR amplification across type-specific polymorphisms in the EBNA2 and EBNA3C genes and across the 30-bp deletion and 33-bp repeat loci in the LMP1 gene and then at the protein level by immunoblotting for the strain-specific "EBNAprint" of EBNA1, -2, and -3C molecular weights. By these criteria, 18 of 35 patients harbored only one detectable EBV strain, usually of type 1, as do healthy carriers. However, the other 17 patients showed clear evidence of multiple infection with different EBV strains. In eight cases these strains were of the same type, again usually type 1, and were more often found coresident in throat washings than in the blood. By contrast, a further nine patients gave evidence of coinfection with type 1 and type 2 strains, and in these cases both virus types were detectable in the blood as well as in the throat. Immunological assays on these HIV-positive patients as a group showed a marked impairment of T-cell responses, reflected in reduced levels of EBV-specific cytotoxic T-cell memory, but an elevation of humoral responses, reflected in raised antibody titers to the EBV envelope glycoprotein gp340 and by the maintenance of virus neutralizing antibodies in serum. We infer that selective impairment of the T-cell system predisposes the host to infection with additional exogenously transmitted EBV strains.

Entities:  

Mesh:

Year:  1996        PMID: 8763991      PMCID: PMC190438     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.

Authors:  R Gavioli; M G Kurilla; P O de Campos-Lima; L E Wallace; R Dolcetti; R J Murray; A B Rickinson; M G Masucci
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

2.  A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals.

Authors:  Q Y Yao; A B Rickinson; M A Epstein
Journal:  Int J Cancer       Date:  1985-01-15       Impact factor: 7.396

3.  Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion.

Authors:  J S Greenspan; D Greenspan; E T Lennette; D I Abrams; M A Conant; V Petersen; U K Freese
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

4.  The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV.

Authors:  K Nilsson; G Klein; W Henle; G Henle
Journal:  Int J Cancer       Date:  1971-11-15       Impact factor: 7.396

5.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

6.  Effect on chemical analyses of beta-propiolactone treatment of whole blood and plasma.

Authors:  M J Ball; D Griffiths
Journal:  Lancet       Date:  1985-05-18       Impact factor: 79.321

7.  Long-term T-cell-mediated immunity to Epstein-Barr virus.

Authors:  A B Rickinson; D J Moss; L E Wallace; M Rowe; I S Misko; M A Epstein; J H Pope
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

8.  A putative transforming gene of Jijoye virus differs from that of Epstein-Barr virus prototypes.

Authors:  H K Adldinger; H Delius; U K Freese; J Clarke; G W Bornkamm
Journal:  Virology       Date:  1985-03       Impact factor: 3.616

9.  Epstein-Barr virus replication in oropharyngeal epithelial cells.

Authors:  J W Sixbey; J G Nedrud; N Raab-Traub; R A Hanes; J S Pagano
Journal:  N Engl J Med       Date:  1984-05-10       Impact factor: 91.245

10.  U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2.

Authors:  T Dambaugh; K Hennessy; L Chamnankit; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

View more
  24 in total

1.  Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.

Authors:  A J Aguirre; E S Robertson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Novel intertypic recombinants of epstein-barr virus in the chinese population.

Authors:  R S Midgley; N W Blake; Q Y Yao; D Croom-Carter; S T Cheung; S F Leung; A T Chan; P J Johnson; D Huang; A B Rickinson; S P Lee
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Strain-dependent requirement for IFN-γ for respiratory control and immunotherapy in murine gammaherpesvirus infection.

Authors:  Ching-Yi Tsai; Zhuting Hu; Weijun Zhang; Edward J Usherwood
Journal:  Viral Immunol       Date:  2011-08       Impact factor: 2.257

4.  Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort.

Authors:  Q Y Yao; D S Croom-Carter; R J Tierney; G Habeshaw; J T Wilde; F G Hill; C Conlon; A B Rickinson
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Koala and Wombat Gammaherpesviruses Encode the First Known Viral NTPDase Homologs and Are Phylogenetically Divergent from All Known Gammaherpesviruses.

Authors:  Paola K Vaz; Carol A Hartley; Sang-Yong Lee; Fiona M Sansom; Timothy E Adams; Kathryn Stalder; Lesley Pearce; George Lovrecz; Glenn F Browning; Christa E Müller; Joanne M Devlin
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

6.  Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains.

Authors:  J M Brooks; D S Croom-Carter; A M Leese; R J Tierney; G Habeshaw; A B Rickinson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

7.  Epstein-Barr virus nuclear antigen 1 interacts with Nm23-H1 in lymphoblastoid cell lines and inhibits its ability to suppress cell migration.

Authors:  Masanao Murakami; Ke Lan; Chitra Subramanian; Erle S Robertson
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

8.  Persistent infection drives the development of CD8+ T cells specific for late lytic infection antigens in lymphocryptovirus-infected macaques and Epstein-Barr virus-infected humans.

Authors:  Nina Orlova; Fred Wang; Mark H Fogg
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

9.  Isolation of intertypic recombinants of Epstein-Barr virus from T-cell-immunocompromised individuals.

Authors:  Q Y Yao; R J Tierney; D Croom-Carter; G M Cooper; C J Ellis; M Rowe; A B Rickinson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

10.  Epstein-barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas.

Authors:  G Habeshaw; Q Y Yao; A I Bell; D Morton; A B Rickinson
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.